

Prof. Taner KORKMAZ

Personal Information

Email: taner.korkmaz@acibadem.edu.tr

Web: <https://avesis.acibadem.edu.tr/taner.korkmaz>

Education Information

Post Doctorate of Medicine, Marmara University, School Of Medicine, Internal Medical Sciences, Turkey 2008 - 2011

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Medical Sciences, 2019 - Continues

Associate Professor, Acibadem Mehmet Ali Aydinlar University, School of Medicine, Department of Medical Sciences, 2014 - 2019

Research Assistant, Marmara University, School Of Medicine, Internal Medical Sciences, 2008 - 2011

Courses

Chemotherapy mechanisms of action, Postgraduate, 2020 - 2021

Anti-hormon treatments, Postgraduate, 2020 - 2021

approach to fertility in patients with breast cancer, education of patients and their relatives, Postgraduate, 2020 - 2021

Follow-up of patients with early stage and metastatic breast cancer, Postgraduate, 2020 - 2021

What is cancer, how does it occur?, Postgraduate, 2020 - 2021

cancer prevention, Undergraduate, 2019 - 2020

Kanser Musculoskeletal Problems Due to Cancer and Its Treatment, Undergraduate, 2019 - 2020

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.**
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., Cicin I., Basal F. B. , et al.
Lung cancer (Amsterdam, Netherlands), vol.148, pp.48-54, 2020 (Journal Indexed in SCI Expanded)
- II. **Pyoderma gangrenosum arising on vinorelbine infusion site with additional histopathological features of syringosquamous metaplasia**
Korkmaz T., Sezer E., Hagverdiyev F., Ozkok S., Cetin E.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020 (Journal Indexed in SCI)
- III. **Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of**

Patients with ALK-Positive NSCLC?

Olmez O. F. , Bilici A., GÜR SOY P., Cubukcu E., Yildiz O., Sakin A., KORKMAZ T., Cil I., ÇAKAR B., Menekse S., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (Journal Indexed in SCI)

- IV. **Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer**
Bilici A., Olmez O. F. , GÜR SOY P., Cubukcu E., Yildiz O., Sakin A., KORKMAZ T., Cil I., ÇAKAR B., Menekse S., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (Journal Indexed in SCI)
- V. **Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey**
KILIÇKAP S., Demirci U., Bugdayci F., Tural D., Korkmaz T., PAYDAŞ S., Yilmaz C., Turna H., Sezer A., Cinkir H. Y. , et al.
JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (Journal Indexed in SCI)
- VI. **Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes**
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M., Aksoy S., Aktas B., Ozdemir O., Alacacioglu A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.1, pp.131-143, 2019 (Journal Indexed in SCI)
- VII. **Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey**
KILIÇKAP S., Ozturk A., Karadurmus N., Korkmaz T., YUMUK P. F. , Cicin I., PAYDAŞ S., Cilbir E., Sakalar T., Uysal M., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.13, no.10, 2018 (Journal Indexed in SCI)
- VIII. **Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients.**
Ozcelik M., Korkmaz T., Odabas H., Gemici C., Ercelep O., Yuksel S., Mert A., Surmeli H., Isik D., Aydin D., et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.37, pp.8901-7, 2016 (Journal Indexed in SCI)
- IX. **Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials**
Korkmaz T., Seber S., Basaran G.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.98, pp.180-188, 2016 (Journal Indexed in SCI)
- X. **Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer.**
Dinc N., Aydin K., Odabas H., Ercelep O., Tufan G., Seker M., Yasar N., Aydin D., Yuksel S., Mert A., et al.
Oncology research and treatment, vol.39, pp.130-4, 2016 (Journal Indexed in SCI)
- XI. **Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.**
Genestreti G., Tiseo M., Kenmotsu H., Kazushige W., Di B., Cavallo G., Carloni F., Bongiovanni A., Burgio M., Casanova C., et al.
Clinical lung cancer, vol.16, 2015 (Journal Indexed in SCI)
- XII. **OUTCOMES OF PLATINUM-SENSITIVE SMALL CELL LUNG CANCER (SCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY RECHALLENGE: A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS**
Genestreti G., Metro G., Kenmotsu H., Carloni F., Burgio M. A. , Casanova C., Tiseo M., Scarpi E., Korkmaz T., Califano R.
JOURNAL OF THORACIC ONCOLOGY, vol.9, no.4, 2014 (Journal Indexed in SCI)
- XIII. **Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience**
Cabuk D., Basaran G., Teomete M., Dane F., Korkmaz T., Seber S., Telli F., Yumuk P., Turhal S.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.1, pp.117-122, 2014 (Journal Indexed in SCI)
- XIV. **COULD PRETREATMENT PET-CT STANDART UPTAKE VALUES HAVE A ROLE IN THE RESPONSE TO TREATMENT AND THE SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?**
Aydin K., Odabas H., Seker M., Korkmaz T., Yasar N., Sener N., Aydin D., Ercelep O., Yuksel S., Mert A. G. , et al.

JOURNAL OF THORACIC ONCOLOGY, vol.8, 2013 (Journal Indexed in SCI)

- XV. **Inducible nitric oxide synthase expression in gastric adenocarcinoma: impact on lymphangiogenesis and lymphatic metastasis.**
Karadayı N., Kandemır N., Yavuzer D., Korkmaz T., Gecmen G., Korkturk F.
Diagnostic pathology, vol.8, pp.151, 2013 (Journal Indexed in SCI)
- XVI. **Primary renal carcinoid: treatment and prognosis.**
Korkmaz T., Seber S., Yavuzer D., Gumus M., Turhal N.
Critical reviews in oncology/hematology, vol.87, pp.256-64, 2013 (Journal Indexed in SCI)
- XVII. **Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer**
Korkmaz T., Seber S., Okutur K., Basaran G., Yumuk F., Dane F., Ones T., Polat O., Madenci O., Demir G., et al.
BIOMARKERS, vol.18, no.1, pp.88-94, 2013 (Journal Indexed in SCI)
- XVIII. **Association between human papillomavirus and endometrial adenocarcinoma.**
Karadayı N., Gecer M., Kayahan S., Yamuc E., Onak N., Korkmaz T., Yavuzer D.
Medical oncology (Northwood, London, England), vol.30, pp.597, 2013 (Journal Indexed in SCI)
- XIX. **Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment.**
Kefeli U., Yildirim M., Aydin D., Madenci O., Yasar N., Sener N., Mert A., Yuksel S., Ercelep O., Korkmaz T., et al.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, vol.17, pp.663-7, 2012 (Journal Indexed in SCI)
- XX. **Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer**
Akun E., Okutur K., Seber S., Korkmaz T., Aydin K., Bozkurt M., Namal E., Hasbal B., Tecimer C., Demir G.
JOURNAL OF BUON, vol.17, no.4, pp.669-676, 2012 (Journal Indexed in SCI)
- XXI. **5-Flourouracil-Induced Encephalopathy in Parkinson's Disease**
Korkmaz T., Seber S., Basaran G., YUMUK P. F. , DANE F., Kocar M., Telli F., Turhal N. S.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.22, no.1, pp.51-53, 2012 (Journal Indexed in SCI)
- XXII. **Clinical outcome of breast cancer patients with N3a (≥ 10 positive lymph nodes) disease: has it changed over years?**
Basaran G., Devrim C., Caglar H., Gulluoglu B., Kaya H., Seber S., Korkmaz T., Telli F., Kocak M., Dane F., et al.
MEDICAL ONCOLOGY, vol.28, no.3, pp.726-732, 2011 (Journal Indexed in SCI)
- XXIII. **Primary small cell carcinoma of the breast: report of seven cases and review of the literature.**
Kanat O., Kilickap S., Korkmaz T., Ustaalioglu O., Canhoroz M., Cubukcu E., Tolunay S., Evrensel T., Manavoglu O.
Tumori, vol.97, pp.473-8, 2011 (Journal Indexed in SCI)
- XXIV. **Assessing cancer-related myths in relatives of cancer patients and the general public: A Turkish Oncology Group study**
Dane F., Turhal N. S. , Unsal D., Sari S., Ulus C. U. , Senturk N., Bingol D., Korkmaz T., Seber S.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXV. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., Basaran G., Yumuk P. F. , Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXVI. **Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.**
Canhoroz M., Korkmaz T., Seber S., Bilici A., Okutur K., Toptas T., Basaran G., Dede F., Yumuk F., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXVII. **Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)**
Korkmaz T., Seber S., Basaran G., Yumuk P. F. , Dane F., Okutur K., Kanitez M., Kocar M., Telli F., Demir G., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- XXVIII. **Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome**
Seber S., Basaran G., Korkmaz T., Telli F., Kocar M., Kanitez M., Dane F., Yumuk P. F. , Turhal N. S.

JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)

XXIX. Primary melanoma of the gallbladder

Korkmaz T, Seber S, Turhal S.

JOURNAL OF BUON, vol.15, no.4, pp.802, 2010 (Journal Indexed in SCI)

XXX. ERCC1 is not expressed in hepatocellular cancer: A Turkish Oncology Group, Gastrointestinal Oncology Subgroup study

Turhal N. S. , BAŞ E., Er O., Aliustaoglu M., Seber S., DANE F., Korkmaz T., Soyuer I., Ozkara S., ÇELİKEL Ç.

JOURNAL OF BUON, vol.15, no.4, pp.794-796, 2010 (Journal Indexed in SCI)

XXXI. Evaluation of expression of ERCC1 in hepatocellular cancer

Bas E., Turhal N. S. , Er O., Aliustaoglu M., Seber S., Dane F., Korkmaz T., Soyuer I., Ozkara S., Celikel C.

JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)

XXXII. A phase II pilot study of weekly docetaxel cisplatin and 5-fluorouracil in metastatic gastric cancer.

Okutur K., Dane F., Ilhan M., Seber S., Korkmaz T., Aydin K., Bozkurt M., Namal E., Turhal N. S. , Demir G.

JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **Three Cases of Breast Metastases from Lung Cancer and Systematic Review of the Literature**
Güldoğan N., Esen İçten G., Tokat F., Tutar B., Kara H., Korkmaz T., Oyan Uluç B., Demir G.
European Journal of Breast Health, vol.17, no.2, pp.200-205, 2021 (Refereed Journals of Other Institutions)
- II. **Evaluation of the association of SNP in carboxylesterase enzyme (CES1) with pharmacokinetic and adverse effects of capecitabine in breast and colorectal cancer patients**
Yuksel M. K. , ÖZTÜRK D., ÖZTAŞ E., Ozhan G., Turker A. A. , Korkmaz T., OKYAR A., Kara Z. P.
ISTANBUL JOURNAL OF PHARMACY, vol.49, no.2, pp.64-69, 2019 (Journal Indexed in ESCI)
- III. **Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study.**
Turhal N. S. , SAVAŞ B., Coskun O., Bas E., KARABULUT B., NART D., Korkmaz T., Yavuzer D., Demir G., Dogusoy G., et al.
Molecular and clinical oncology, vol.3, no.6, pp.1275-1279, 2015 (Journal Indexed in ESCI)
- IV. **Metastasis-Induced Acute Pancreatitis Successfully Treated with Chemotherapy and Radiotherapy in a Patient with Small Cell Lung Cancer.**
Okutur K., Bozkurt M., Korkmaz T., Karaaslan E., Guner L., Goksel S., Demir G.
Case reports in oncological medicine, vol.2015, pp.304279, 2015 (Refereed Journals of Other Institutions)

Refereed Congress / Symposium Publications in Proceedings

- I. **Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).**
Basaran G., Korkmaz T., Kara H., Boler D., Kapucuoglu N., Uras C., Saglican Y., Ince Ü.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- II. **Prognostic role of progesterone receptor expression by immunohistochemistry in relation to oncotype recurrence scores**
KORKMAZ T., BAŞARAN G., KAPUCUOGLU N., SAĞLICAN Y., BEŞE N., İÇTEN G. E. , URAS C., İNCE Ü.
international İstanbul Breast Cancer Conference, İstanbul, Turkey, 30 September - 02 October 2014
- III. **THREE DIFFERENT CHEMOTHERAPY COMBINATIONS WITH CONCURRENT THORACIC RADIATION FOR PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER**
Ozcelik M., Balvan Ercelep O., Guven Mert A., Yuksel S., Ozdemir P., Surmeli H., Isik D., Aydin D., Korkmaz T., Odabas H., et al.

39th ESMO Congress (ESMO), Madrid, Spain, 26 - 30 September 2014, vol.25

- IV. **Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis**
Genestreti G., Metro G., Kenmotsu H., Wakuda K., Di Battista M., Cavallo G., Franceschi E., Bartolotti M., Carloni F., Bongiovanni A., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- V. **The relationship between tumor markers and histopathologic and demographic features of patients with breast cancer and their distinctive role in metastatic process.**
Aydin K., Uygur M. M., Odabas H., Korkmaz T., Yasar N., Dinc N., Aydin D., Yuksel S., Balvan O., Guven A., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- VI. **The relationship between collapsin response mediator protein-1 (CRMP 1) expression and histopathologic parameters and survival in patient with gastric cancer.**
Gumus M., Yasar N., Kayahan S., Yuksel S., Balvan O., Mert A. G., Dinc N., Aydin D., Aydin K., Odabasi H., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- VII. **THE PROGNOSTIC SIGNIFICANCE OF TYMIDINE KINASE ACTIVITY LEVELS IN METASTATIC COLORECTAL CANCER**
Seber E. S., Korkmaz T., Okutur K., DANE F., YUMUK P. F., Aktas B., Kanitez M., Demir G., Turhal S. N.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.217
- VIII. **COMPARISON OF SECOND LINE TREATMENT OUTCOMES BETWEEN SENSITIVE AND REFRACTORY SMALL CELL LUNG CANCER PATIENTS: A RETROSPECTIVE ANALYSIS**
Korkmaz T., Seber S., SARI E., Canhoroz M., Ustaalioglu B. O., Kefeli U., Balvan O., Gumus M., Yasar N., Turhal S. N.
37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.497-498
- IX. **Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. Single center experience**
Cabuk D., Basaran G., Korkmaz T., Seber S., DANE F., Telli F., Yumuk F., Turhal N. S.
European Breast Cancer Conference, Barcelona, Spain, 24 March 2010, vol.8, pp.205

Citations

Total Citations (WOS):211

h-index (WOS):9